DENVER, Colo. (247marketnews.com) -- There is insider buying and then there is insider buying that arrives at exactly the moment a biotech story gets exciting. For NeOnc Technologies Holdings (NASDAQ:NTHI), CEO, President and director Amir F. Heshmatpour reported another open-market purchase last week: 37,000 shares at a weighted-average price of $3.6654, an investment of roughly $135,620.
The timing is hard to ignore.
NeOnc recently announced a $15 million registered direct offering priced at $4.20 per share and accompanying warrant. Heshmatpour's purchase therefore came at a price roughly 13% below that financing price, a detail that gives the transaction an especially interesting edge.
It also means the company's top executive was not merely buying into a freshly announced financing. He was buying shares in the open market after the financing had been priced, which is the kind of transaction biotech traders tend to notice, and Heshmatpour is hardly a first-time buyer.
NeOnc's insider-buying trail has been building for months. In August, Heshmatpour bought another 15,000 shares across August 14 and August 17, followed by 9,000 shares on August 18. Founder and Chief Scientific Officer Thomas C. Chen was buying as well, including purchases totaling roughly $350,000 across several August transactions.
Taken together, the pattern is considerably more interesting than a one-off insider purchase.
The obvious question is: what are they seeing?
The answer may lie in NeOnc's rapidly changing clinical story.
In August, the company reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. The study reported six-month progression-free survival of 48.9%, versus a pre-specified 20% benchmark, with a reported median overall survival of 26.09 months. Five of 24 patients remained on treatment, including one patient with progression-free survival approaching 19 months and another with an ongoing partial response.
NeOnc also reported no major toxicities across the cohort, although the company cautioned that the study was small, open-label and single-arm.
Still, the data produced a potentially powerful catalyst: NeOnc said it intends to request a Type B meeting with the FDA to discuss a registrational development path for NEO100.
CEO Heshmatpour put the company's ambitions plainly after the readout: “Our priority now is to engage with the FDA and align on the most efficient path toward a registrational study.”
That is the bull case in one sentence.
NEO100 is designed to attack one of the central problems in brain-cancer drug development: getting therapeutics into the brain. The company's approach uses intranasal delivery, with the drug intended to reach the brain along olfactory and trigeminal pathways rather than relying on conventional systemic delivery to overcome the blood-brain barrier.
If the Phase 2a signal survives additional scrutiny and ultimately translates into a successful registrational program, the commercial implications could be significant.
That makes the CEO's decision to put more money into NTHI particularly notable.
The insider activity is not happening in a vacuum, either.
Earlier this year, Heshmatpour embarked on a much more aggressive buying campaign. NeOnc disclosed in April that he had purchased approximately $300,000 of NTHI shares over the preceding week.
The company itself highlighted Heshmatpour's conviction at the time.
In April, the company said his purchases reflected confidence in the shares ahead of catalysts including NEO100 data and regulatory work surrounding NEO212. Heshmatpour later described his buying as reflecting “my conviction in NeOnc’s long-term opportunity and clinical direction.”
Now the story has moved forward.
The NEO100 data catalyst has arrived. The company is pursuing FDA discussions. NEO212 is advancing toward Phase 2 development, with the FDA having previously provided written feedback concerning its CMC development and capsule-to-tablet transition and NeOnc has just raised another $15 million from institutional investors.
Against that backdrop, Heshmatpour is still buying.
That does not prove NTHI is headed higher. Insider purchases are signals of personal capital allocation, not guarantees of clinical success, FDA approval or shareholder returns, but it does change the texture of the story.
The market is being asked to digest three competing forces at once: promising but early clinical data, a fresh capital raise that brings dilution, and unusually persistent insider buying, which is exactly the kind of setup that can produce exciting moves in a small-cap biotech.
For NTHI bulls, the argument is straightforward: management has repeatedly put its own money behind the company while the clinical narrative is moving from speculative promise toward a potential regulatory pathway.
For skeptics, the counterargument is just as straightforward: NEO100 still needs to prove that encouraging Phase 2a results can translate into a larger, controlled development program.
Either way, the 37,000-share purchase last week adds another chapter.
The headline number is only about $136,000, but the bigger signal is the persistence.
After months of buying, a major clinical readout, a new financing and an emerging FDA catalyst, NeOnc's CEO is still reaching into his own pocket for NTHI.
That makes the next FDA conversation and the next clinical milestone far more interesting than it would have been a few months ago and the insiders have made their bet.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
